GNMSF GENMAB AS
- 291.540
- +3.740+1.30%
GENMAB AS News
6-K: Report of foreign private issuer (related to financial reporting)
Transactions in Connection With Share Buy-back Program Genmab
Genmab Announces Net Sales of DARZALEX (Daratumumab) for First Quarter of 2024
Genmab to Purchase US-based Biotech Company ProfoundBio for $1.8 Billion in All-cash Deal
Genmab to Broaden and Strengthen Oncology Portfolio With Acquisition of ProfoundBio
Completion of Share Buy-back Program
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
Passing of Genmab A/S' Annual General Meeting
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Transactions in Connection With Share Buy-back Program
Genmab Files Annual Report With the U.S. Securities and Exchange Commission
Genmab Announces Initiation of Share Buy-Back Program
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Genmab Announces Net Sales of DARZALEX (Daratumumab) for 2023
Genmab Announces Decision in Arbitration Appeal Under License Agreement With Janssen
BTIG Analyst Rates Genmab as 'Buy' Citing Solid Financials and Strategic Growth Moves
Argenx, Genmab in Pact to Study Antibody Therapies for Immunology and Oncology
AbbVie Pins Hopes on Newer Drugs and Deals to Face Humira Knockoffs – WSJ
Genmab Files for Approval of Blood Cancer Therapy Epcoritamab in Japan
Analysis
Price Target
No Data
